Canis ISSN: 2398-2942

Eye: keratoconjunctivitis sicca

Synonym(s): Dry eye

Contributor(s): Dennis E Brooks, David L Williams, Alison Clode

Introduction

  • Ocular surface disease resulting from deficient production of aqueous phase of precorneal tear film.
  • May involve decreased production of lipid or mucin portions of tear film, leading to qualitative (rather than quantitative) tear film deficiency (more difficult to diagnose).
  • Cause: congenital lacrimal gland asplasia or hypoplasia; secondary to systemic metabolic disease (diabetes mellitus), drug induced (sulphonamide antibiotics, etogesic, general anesthetics, sedatives, anticholinergics); damage to local parasympathetic innervation (trauma, local inflammation, radiation therapy); auto-immune destruction of lacrimal gland; idiopathic.
  • Signs: mucoid to mucopurulent ocular discharge; conjunctival hyperemia; lackluster ocular surface; corneal edema, vascularization and pigmentation (depending on chronicity); corneal ulceration (potentially recurrent). Keratoconjunctivitis sicca West Highland White male 3 years
  • Diagnosis: combination of clinical signs and low Schirmer tear test (<15 mm wetting/min) is diagnostic for quantiative deficiency of KCS. Qualitative deficiency (lipid and/or mucin layers) leads to clinical signs with normal STT, and is definitely diagnosed via tear film break-up time (uncommonly performed).
  • Treatment: palliative medical therapy consisting of topical artificial tears, prophylactic antibiotics (if sedonary bacterial infection present), and/or anti-inflammatories. Treat underlying cause if possible. Depending upon underlying cause, topical cyclosporine A or oral pilocarpine to stimulate tear production. Surgical therapy (parotid duct transposition) in non-responsive cases.
  • Prognosis: if congenital, unlikely to respond to medical management. May be reversible if secondary to systemic disease. If drug-induced, may be temporary/reversible or irreversible. If due to interrupted parasympathetic innervation, may be responsive to medical management. Auto-immune cases in susceptible breeds generally progressive, life-long treatment necessary. Loss of eye rare, with good owner compliance and monitoring.
    Print off the owner factsheet Keratoconjunctivitis sicca ('Dry eye') Keratoconjunctivitis sicca ('Dry eye') to give to your client.

Pathogenesis

Etiology

  • Congenital - aplasia/hypoplasia of lacrimal and/or nictitans gland. Seen in Cavalier King Charles Spaniels, Yorkshire terriers.
  • Acquired:
    • Immune-mediated.
    • Drug-induced (sulfonamides, salicylic acid, topical atropine).
    • Metabolic disease (hypothyroidism Hypothyroidism, diabetes mellitus, hyperadrenocorticism).
    • Neurogenic (damage to facial VII nerve, carries motor parasympathetic fibers to lacrimal and nictitans glands).
    • Radiotherapy.
    • Systemic infectious disease (canine distemper Canine distemper disease.
    • Trauma involving lacrimal gland (bite wounds, skull or orbital fractures).
    • Idiopathic.
    • Iatrogenic - surgical removal of nictitans gland.

Predisposing factors

  • Breed predisposition.

 

Pathophysiology

  • In the dog, lacrimal gland produces 70% of aqueous phase of precorneal tear film and nictitans gland produces 30% with minor contributions from modified sweat glands in lid margin (glands of Moll).
  • Partial or total absence or destruction of lacrimal gland +/- nictitans gland reduced production of aqueous phase of precorneal tear film (ptf).
  • Compensatory overproduction of mucous phase.
  • Secondary infection resulting from loss of bacteriostatic/bacteriocidal factors in aqueous phase, eg lysozyme.
  • Decreased production of outer lipid layer of tear film leads to premature evaporation of aqueous portion, while decreased production of inner mucin layer leads to poor adherence to ocular surface. These conditions lead to qualitative tear film deficiency, which has similar signs to quantitative deficiency, but may have normal STT result.

Timecourse

  • Can be acute in onset or more insidious.

Diagnosis

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Treatment

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Outcomes

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Sansom J, Barnett K C, Neuman W et al (1995) Treatment of keratoconjunctivitis sicca​ in dogs with cyclosporine ophthalmic ointment- a European clinical trial field. Vet Rec 137 (20), 504-507 PubMed.
  • Stiles J, Carmicheal P, Kaswan R et al (1995) Keratectomy for corneal pigmentation in dogs with cyclosporine responsive chronic keratoconjunctivitis sicca. Vet Comp Ophthal 5 (1), 25-34 VetMedResource.
  • Morgan R V & Abrams K L (1991) Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. JAVMA 199 (8), 1043-6 PubMed.
  • Salisbury M A, Kaswan R L & Ward D A et al (1990) Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs. JAAHA 26 (3), 269-74 VetMedResource.

Other sources of information

  • Gelatt K N (2013)Veterinary Ophthalmology.5th edn. John Wiley & Sons.


ADDED